The HemOnc Pulse

The HemOnc Pulse


Latest Episodes

Dr. Usmani Discusses Perseus, IsKia, Data Plus More Myeloma Updates
December 18, 2023

Saad Usmani, MD, MBA, FACP, Chief of the Myeloma Service at the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, on The HemOnc Pulse to chat about the latest research in mult

Dr. Venugopal Offers Her Thoughts on the Latest MDS News
December 17, 2023

Sangeetha Venugopal, MD, of the University of Miami Sylvester Comprehensive Cancer Center, offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes (MDS), the CO

Jerald Radich, MD: AML Abstracts to Keep an Eye on at ASH 2023
December 17, 2023

In this episode of The HemOnc Pulse, Jerald Radich, MD, of the Fred Hutchinson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss various abstracts on acute myeloid leukemia (AML) presented

Inside the FDA ODAC ’Yes’ Vote to Polivy
November 30, 2023

In this episode of The HemOnc Pulse, Grzegorz Nowakowski MD, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic, recounts his experience serving on the FDA Oncologic

Kami Maddocks, MD, on the Shocking Ibrutinib Withdrawal
November 16, 2023

In this episode of The HemOnc Pulse, Dr. Maddocks, Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University, charts the treatment evolution of mantle cell lym

Jorge Cortes, MD, on Why Balance Is Key in CML Therapy
November 02, 2023

Dr. Cortes, who serves as Director of the Georgia Cancer Center at Augusta University, joins host Chadi Nabhan, MD, MBA, FACP, to chat about the boom in treatments for chronic myeloid leukemia (CML)

What Are the Top Questions in ALL?
October 19, 2023

Elias Jabbour, MD, of the University of MD Anderson Cancer Center stops by The HemOnc Pulse for a live show at the Eleventh Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.In

The ABCs of MM Treatment According to Rafael Fonseca, MD
October 05, 2023

Dr. Fonseca offers his thoughts on the future of multiple myeloma (MM) treatment, the ongoing debate between chimeric antigen receptor (CAR)-T therapies and bispecifics, and the latest treatment news

The Post-POLARIX Trial Era: Polatuzumab Vedotin Shifts DLBCL Treatment
September 14, 2023

On this episode of The HemOnc Pulse, guest Jonath

Dr. Garcia-Manero on the Data Behind the Luspatercept Approval
September 13, 2023

Guillermo Garcia-Manero, MD, of the University of